Share Price | Rekvina Labs Ltd Stock Analysis & Recommendation

Q: When is the next results date for Rekvina Labs Ltd?

The next results date for Rekvina Labs Ltd is scheduled for 06 February 2026.

Q: Should I buy, sell or hold Rekvina Labs Ltd?

Based on the current situation with Rekvina Labs Ltd, it would be advisable to consider selling your shares. The company has shown flat results as of September 19, and there have been no results reported in the last six months, which indicates a lack of transparency and potential issues within the business. Additionally, the stock is trading at a risky level compared to its historical valuations. Over the past year, the stock has not generated any returns, and profits have decreased by 17%. Given these factors, holding or buying more shares may not be a prudent decision at this time.

Q: Why is Rekvina Labs Ltd falling/rising?

As of 10-Apr, Rekvina Labs Ltd's stock price is rising, currently at Rs.39.87, which reflects an increase of Rs.0.78 or 2.0%. This upward movement is supported by several factors. Over the past week, the stock has gained 6.04%, outperforming the Sensex, which increased by 5.77%. In the last month, Rekvina Labs has shown a remarkable increase of 36.03%, while the Sensex has declined by 0.84%. Today, the stock reached a new 52-week high of Rs.39.87 and has been on a consecutive gain streak for the last four days, accumulating a total return of 8.2% during this period. Additionally, Rekvina Labs is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a strong bullish trend. However, it is worth noting that there has been a significant drop in investor participation, with delivery volume on April 9 falling by 88.89% compared to the 5-day average. Despite this decline in participation, the stock remains liquid enough for trading, suggesting that the price increase is driven by existing investor confidence rather than new inflows. Overall, the combination of strong recent performance and positive technical indicators contributes to the rising stock price of Rekvina Labs Ltd.

52-Week High: Rs.39.87 hit today

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

900 (-90.74%) Volume

Shareholding (Jun 2021)

FII

0.00%

Held by 0 FIIs

DII

0.00%

Held by 0 DIIs

Promoter

41.30%

When is the next results date for Rekvina Labs Ltd?

30-Jan-2026

The next results date for Rekvina Labs Ltd is 06 February 2026.

View full answer

Should I buy, sell or hold Rekvina Labs Ltd?

07-Feb-2026

Why is Rekvina Labs Ltd falling/rising?

10-Apr-2026

As of 10-Apr, Rekvina Labs Ltd's stock price is rising to Rs.39.87, reflecting a 2.0% increase. The stock has gained 36.03% over the past month, outperforming the Sensex, despite a significant drop in investor participation.

View full answer

Which are the latest news on Rekvina Labs?

11-Apr-2026

Broad-Based Technical Strength Lifts Rekvina Labs Ltd to 52-Week High of Rs 39.87
Broad-Based Technical Strength Lifts Rekvina Labs Ltd to 52-Week High of Rs 39.09

Compare Rekvina Labs with Similar Stocks

Sun Pharma.Inds.Cresanto Global Divi's Lab.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Net Sales has grown by an annual rate of % and Operating profit at 0% over the last 5 years
High Debt Company with a Debt to Equity ratio (avg) at 0 times

Flat results in Sep 19

Risky - Negative EBITDA

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

Industry

Pharmaceuticals & Drugs

Market cap

INR 24 Cr (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.02

Return on Equity

-25.10%

Price to Book

-23.56

Revenue and Profits:

Net Sales:

0 Cr

(Quarterly Results - Dec 2025)

Net Profit:

0 Cr

Total Returns

Total Returns (Price + Dividend)

Company does not have enough history

Risk Adjusted Returns v/s

Returns Beta

Beta has not been calculated since enough price history is not available

News & Corporate Actions

News

Broad-Based Technical Strength Lifts Rekvina Labs Ltd to 52-Week High of Rs 39.87

Surging past its previous peaks, Rekvina Labs Ltd reached a new 52-week high of Rs 39.87 on 10 Apr 2026, propelled by a confluence of bullish technical indicators and sustained price momentum over recent sessions.

Read full news article

Broad-Based Technical Strength Lifts Rekvina Labs Ltd to 52-Week High of Rs 39.09

With a decisive break above Rs 39.09 on 9 Apr 2026, Rekvina Labs Ltd has reached a fresh 52-week high, propelled by a confluence of bullish technical indicators and sustained price momentum despite a broadly weakening market backdrop.

Read full news article

Broad-Based Technical Strength Lifts Rekvina Labs Ltd to 52-Week High of Rs 38.35

With a sustained rally over the past 15 trading sessions, Rekvina Labs Ltd has surged to a fresh 52-week high of Rs 38.35 on 6 Apr 2026, marking a remarkable 33.34% gain during this period. This price milestone is underscored by a confluence of bullish technical indicators that highlight strong momentum despite a broadly weakening market backdrop.

Read full news article

Announcements

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018

06-Apr-2026 | Source : BSE

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018.

Compliances-Reg.24(A)-Annual Secretarial Compliance

06-Apr-2026 | Source : BSE

Non Applicability of Reg- 24(A) - Annual Secretarial Compliance Report

Announcement under Regulation 30 (LODR)-Open Offer - Updates

02-Apr-2026 | Source : BSE

Update on Open Offer

Corporate Actions

BOARD MEETING

No Upcoming Board Meetings

DIVIDEND

No Dividend history available

SPLITS

Rekvina Labs Ltd has announced 5:10 stock split, ex-date: 30 Apr 14

BONUS

No Bonus history available

RIGHTS

No Rights history available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

0.00%

EBIT Growth (5y)

0.00%

EBIT to Interest (avg)

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.02

Sales to Capital Employed (avg)

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

-6.82%

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-24.03

EV to EBIT

-24.26

EV to EBITDA

-24.26

EV to Capital Employed

-24.26

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

Bullish

Bearish

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bullish

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Jun 2021

Shareholding Compare (%holding)

Majority shareholders

Non Institution

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 0 FIIs

Promoter with highest holding

Surbhit Mukesh Shah (15.22%)

Highest Public shareholder

Viralkumar Tribhovandas Patel (4.388%)

Individual Investors Holdings

51.98%

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 75.00% vs 0.00% in Sep 2025",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -300.00% vs -50.00% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.35",
          "val2": "0.20",
          "chgp": "75.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.12",
          "val2": "-0.03",
          "chgp": "-300.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-0.12",
          "val2": "-0.03",
          "chgp": "-300.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-34.29%",
          "val2": "-15.00%",
          "chgp": "-19.29%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "alert": "No Half Yearly Results declared by Rekvina Labs"
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "alert": "No Nine Monthly Results declared by Rekvina Labs"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.14",
          "val2": "-0.08",
          "chgp": "-75.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-0.14",
          "val2": "-0.08",
          "chgp": "-75.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

0.35

0.20

75.00%

Operating Profit (PBDIT) excl Other Income

-0.12

-0.03

-300.00%

Interest

0.00

Exceptional Items

0.00

Standalone Net Profit

-0.12

-0.03

-300.00%

Operating Profit Margin (Excl OI)

-34.29%

-15.00%

-19.29%

Values in Rs Cr.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 75.00% vs 0.00% in Sep 2025

Standalone Net Profit

QoQ Growth in quarter ended Dec 2025 is -300.00% vs -50.00% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Standalone) - Mar'25

Mar'25

Mar'22

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-0.14

-0.08

-75.00%

Interest

0.00

Exceptional Items

0.00

Standalone Net Profit

-0.14

-0.08

-75.00%

Operating Profit Margin (Excl OI)

0.00%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Annual Results

Company CV

About Rekvina Labs Ltd

Rekvina Labs Ltd

Micro Cap

Pharmaceuticals & Drugs

Rekvina Labs Limited was incorporated on 1st November 1988. From a small domestic company at inception in middle of 80's, Rekvina has grown formidably to be an integrated, Indian pharmaceutical company with sales in excess of Rs 20 Crore. It is registered in England and Wales as a Public Limited Company. The Company is a Quality producer of Pharmaceutical formulations for its customer as per their specific requirements. It provide contract research and manufacturing services to customers.

Company Coordinates

Company Details

328 Paradise Complex, Sayajigunj Vadodara Gujarat : 390005

Tel: 91-265-2362966

http://www.rekvinalaboratories.com

rekvina@gmail.com

Registrar Details

Purva Shareregistry (India) Pvt Ltd , Gala No 9, Shiv Shakti, Industrial Estate,Sitaram Mill Comp., J R Boricha Marg, Lower Parel [E], Mumbai